SPRO
Price
$1.59
Change
+$0.02 (+1.27%)
Updated
May 17, 6:59 PM EST
82 days until earnings call
XNCR
Price
$23.03
Change
+$0.57 (+2.54%)
Updated
May 17, 6:59 PM EST
74 days until earnings call
Ad is loading...

SPRO vs XNCR

Header iconSPRO vs XNCR Comparison
Open Charts SPRO vs XNCRBanner chart's image
Spero Therapeutics
Price$1.59
Change+$0.02 (+1.27%)
Volume$126.05K
CapitalizationN/A
Xencor
Price$23.03
Change+$0.57 (+2.54%)
Volume$386.58K
CapitalizationN/A
View a ticker or compare two or three
SPRO vs XNCR Comparison Chart

Loading...

SPRODaily Signal changed days agoGain/Loss if shorted
 
Show more...
XNCRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
SPRO vs. XNCR commentary
May 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPRO is a StrongBuy and XNCR is a Hold.

COMPARISON
Comparison
May 18, 2024
Stock price -- (SPRO: $1.59 vs. XNCR: $23.03)
Brand notoriety: SPRO and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPRO: 53% vs. XNCR: 103%
Market capitalization -- SPRO: $85.84M vs. XNCR: $1.42B
SPRO [@Biotechnology] is valued at $85.84M. XNCR’s [@Biotechnology] market capitalization is $1.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $593.52B to $0. The average market capitalization across the [@Biotechnology] industry is $2.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPRO’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • SPRO’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRO’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • SPRO’s TA Score: 5 bullish, 5 bearish.
  • XNCR’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than XNCR.

Price Growth

SPRO (@Biotechnology) experienced а -3.05% price change this week, while XNCR (@Biotechnology) price change was +2.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.

Reported Earning Dates

SPRO is expected to report earnings on Aug 08, 2024.

XNCR is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Biotechnology (+1.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for SPRO with price predictions.
OPEN
A.I.dvisor published
a Summary for XNCR with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
XNCR($1.42B) has a higher market cap than SPRO($85.8M). XNCR (8.479) and SPRO (8.163) have similar YTD gains .
SPROXNCRSPRO / XNCR
Capitalization85.8M1.42B6%
EBITDAN/AN/A-
Gain YTD8.1638.47996%
P/E Ratio3.61N/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
SPRO vs XNCR: Fundamental Ratings
SPRO
XNCR
OUTLOOK RATING
1..100
1863
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4094
PRICE GROWTH RATING
1..100
4948
P/E GROWTH RATING
1..100
946
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (26) in the Pharmaceuticals Major industry is somewhat better than the same rating for XNCR (79) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than XNCR’s over the last 12 months.

SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as XNCR (100) in the Biotechnology industry. This means that SPRO’s stock grew similarly to XNCR’s over the last 12 months.

SPRO's SMR Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for XNCR (94) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's Price Growth Rating (48) in the Biotechnology industry is in the same range as SPRO (49) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to SPRO’s over the last 12 months.

XNCR's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for SPRO (94) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew significantly faster than SPRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SPROXNCR
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 1 day ago
69%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
SPRODaily Signal changed days agoGain/Loss if shorted
 
Show more...
XNCRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEGIX28.110.65
+2.37%
First Eagle Gold I
ETNDX17.850.02
+0.11%
Eventide Dividend Opportunities N
DSCVX29.52N/A
N/A
BNY Mellon Opportunistic Small Cap Inv
GGYPX15.65N/A
N/A
Goldman Sachs Focused Value P
JGVVX39.08-0.02
-0.05%
JPMorgan Growth Advantage R6

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with PYXS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then PYXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+1.27%
PYXS - SPRO
37%
Loosely correlated
-0.48%
IMAB - SPRO
34%
Loosely correlated
-1.13%
LXRX - SPRO
34%
Loosely correlated
-3.80%
XNCR - SPRO
34%
Loosely correlated
+2.54%
OCUL - SPRO
33%
Poorly correlated
-1.59%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+2.54%
VCYT - XNCR
52%
Loosely correlated
-2.22%
NTLA - XNCR
50%
Loosely correlated
+0.19%
PRME - XNCR
50%
Loosely correlated
+0.57%
BEAM - XNCR
49%
Loosely correlated
+3.49%
RLAY - XNCR
47%
Loosely correlated
+2.00%
More